GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Guizhou Bailing Group Pharmaceutical Co 002424.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

4.40

-0.68%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Guizhou Bailing Group Pharmaceutical Co

Its shares trade on Shenzhen under the ticker 002424.SZ. It has been listed since 3 June 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.05bn and a net loss of CN¥104.4m. At that date it held total assets of CN¥6.20bn and shareholders' equity of CN¥3.16bn.

Guizhou Bailing Group Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicines. The company is headquartered in Anshun, Guizhou. The company went IPO on 2010-06-03. The firm is also engaged in the provision of Chinese medicine materials. The firm is also engaged in the distribution of fertilizers and purified water, and the operation of medical institutions. The firm conducts its businesses mainly within domestic markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
3 Jun 2010
Employees
6,138
Website
gzbl.com ↗

Leadership

Pay as last reported

  • Mr. Wei JiangChairman of the Board, Acting Secretary of the Board, since 2007CN¥1.2m
  • Mr. Hongxing LiChief Financial OfficerCN¥480,000
  • Mr. Min NiuGeneral Manager, Director, since 2007CN¥720,000
  • Mr. Pei ChenDeputy General Manager, Director, since 2013CN¥720,000
  • Mr. Jixian FengDeputy General ManagerCN¥720,000
  • Mr. Yuanzhen YuanExecutive Deputy General ManagerCN¥720,000
  • Mr. Maoxue ZhengDeputy General ManagerCN¥720,000
  • Mr. Yong JiangDirector, since 2007CN¥720,000
  • Mr. Yifeng ZhouDirectorCN¥720,000
  • Mr. Jian HuIndependent DirectorCN¥60,000
  • Ms. Guowan YanIndependent DirectorCN¥60,000
  • Mr. Ming YangIndependent DirectorCN¥60,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
38
Environment
33
Social
21
Governance
61
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Anshun, Guizhou with 6,138 employees.
  • Engages in R&D, production, and sale of Chinese medicines.
  • Conducts business mainly within domestic markets.

Weaknesses

  • Engaged in fertilizer and purified water distribution, which may dilute core focus.
  • Operations include medical institutions, which may increase operational complexity.
  • Reliance on domestic markets limits international growth potential.

Opportunities

  • Expansion into international markets for Chinese medicine sales.
  • Growth potential in the provision of Chinese medicine materials.
  • Potential for increased R&D investment in pharmaceuticals.

Threats

  • Competition from other pharmaceutical companies in domestic market.
  • Regulatory changes affecting Chinese medicine industry.
  • Economic downturns impacting domestic market demand.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.